PD-L1 Expression and Lymphocytic Response in Neoadjuvant-Treated Breast Cancers

被引：0
|
作者：
Schatz-Siemers, Nina
Harrison, Beth
Formenti, Silvia C.
Demaria, Sandra
机构：
[1] NYU, Langone Med Ctr, New York, NY USA
[2] Weill Cornell Med Coll, New York, NY USA
来源：
LABORATORY INVESTIGATION | 2016年 / 96卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
275
引用
收藏
页码：70A / 71A
页数：2
相关论文
共 50 条
  • [1] PD-L1 Expression and Lymphocytic Response in Neoadjuvant-Treated Breast Cancers
    Schatz-Siemers, Nina
    Harrison, Beth
    Formenti, Silvia C.
    Demaria, Sandra
    MODERN PATHOLOGY, 2016, 29 : 70A - 71A
  • [2] Correlation of PD-L1 expression with toxicities and response in oropharyngeal cancers treated with definitive chemoradiotherapy
    Srivastava, Smriti
    Rastogi, Madhup
    Gandhi, Ajeet Kumar
    Khurana, Rohini
    Hadi, Rahat
    Sapru, Shantanu
    Srivastava, Anoop
    Bharati, Avinav
    Husain, Nuzhat
    Mishra, Surendra Prasad
    Sahni, Kamal
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2022, 26 (03): : 180 - 186
  • [3] An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response
    Didem Naz Dioken
    Ibrahim Ozgul
    Irem Yilmazbilek
    Mustafa Cengiz Yakicier
    Ezgi Karaca
    Ayse Elif Erson-Bensan
    Cancer Immunology, Immunotherapy, 2023, 72 : 4065 - 4075
  • [4] An alternatively spliced PD-L1 isoform PD-L1△3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response
    Dioken, Didem Naz
    Ozgul, Ibrahim
    Yilmazbilek, Irem
    Yakicier, Mustafa Cengiz
    Karaca, Ezgi
    Erson-Bensan, Ayse Elif
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (12) : 4065 - 4075
  • [5] An alternatively spliced PD-L1 isoform PD-L1Δ3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response
    Dioken, Didem Naz
    Ozgul, Ibrahim
    Yilmazbilek, Irem
    Yakicier, Mustafa Cengiz
    Karaca, Ezgi
    Erson-Bensan, Ayse Elif
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023,
  • [6] PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy
    Alhesa, Ahmad
    Awad, Heyam
    Bloukh, Sarah
    Al-Balas, Mahmoud
    El-Sadoni, Mohammed
    Qattan, Duaa
    Azab, Bilal
    Saleh, Tareq
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2022, 36
  • [7] PD-L1 expression in TNBC: A predictive biomarker of response to neoadjuvant chemotherapy?
    Botticelli, A.
    Cerbelli, B.
    Pernazza, A.
    Onesti, C. E.
    Sciattella, P.
    Costarelli, L.
    Monti, M.
    Campagna, D.
    Mazzuca, F.
    Fortunato, L.
    Marchetti, P.
    D'Amati, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
    Cerbelli, Bruna
    Pernazza, Angelina
    Botticelli, Andrea
    Fortunato, Lucio
    Monti, Massimo
    Sciattella, Paolo
    Campagna, Domenico
    Mazzuca, Federica
    Mauri, Maria
    Naso, Giuseppe
    Marchetti, Paolo
    d'Amati, Giulia
    Costarelli, Leopoldo
    BIOMED RESEARCH INTERNATIONAL, 2017, 2017
  • [9] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [10] PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
    Wimberly, Hallie
    Brown, Jason R.
    Schalper, Kurt
    Haack, Herbert
    Silver, Matthew R.
    Nixon, Christian
    Bossuyt, Veerle
    Pusztai, Lajos
    Lannin, Donald R.
    Rimm, David L.
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (04) : 326 - 332
12345